Medical experts said that starting testosterone replacement therapy (TRT) too early can shut down the body's natural production of the hormone [1].

This caution comes as the prevalence of hormone treatments grows. With more than 11 million Americans prescribed testosterone [2], the potential for long-term endocrine disruption and surgical complications has become a significant public health concern.

Dr. Payal Kohli, a medical expert appearing in a 9 News Australia segment, explained the biological impact of the treatment. "TRT could turn off your body's natural function of creating testosterone," Kohli said [1]. This occurs because exogenous testosterone signals the hypothalamic-pituitary-gonadal axis to reduce its own internal production [1].

Recent data suggests these hormonal shifts may correlate with higher medical risks during recovery from surgery. Research released March 2, 2026, linked testosterone therapy with serious health risks following total knee replacement surgery [3]. The study indicates that patients on TRT may face increased postoperative complications compared to those not using the therapy [3].

Despite these warnings, the medical community remains divided on the accessibility of these drugs. An FDA panel previously advocated for loosening restrictions to expand access to testosterone medications [4]. Some experts have even described the hormone as a "miracle drug" and supported its broader use [5].

However, urologists and men's health specialists continue to advise caution. These practitioners said that the risks of premature initiation, such as the permanent suppression of natural hormone levels, outweigh the immediate benefits for many patients [5].

Medical providers are encouraged to conduct thorough screenings before prescribing TRT to ensure patients are not starting the therapy before it is clinically necessary [1].

“"TRT could turn off your body's natural function of creating testosterone."”

The tension between the FDA's push for broader access and the warnings from specialists highlights a growing conflict in men's health. While TRT offers symptomatic relief, the risk of permanent endocrine shutdown and increased surgical complications suggests that the 'miracle drug' narrative may overlook critical long-term safety profiles.